About PharmaCyte Biotech, Inc.
https://pharmacyte.comPharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States.
CEO
Joshua N. Silverman
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2021-07-12 | Reverse | 1:1550 |
| 2003-12-08 | Forward | 3:1 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
GEODE CAPITAL MANAGEMENT, LLC
Shares:126.6K
Value:$115.84K
AYRTON CAPITAL LLC
Shares:92.09K
Value:$84.26K
EQUITEC PROPRIETARY MARKETS, LLC
Shares:82.73K
Value:$75.7K
Summary
Showing Top 3 of 28
About PharmaCyte Biotech, Inc.
https://pharmacyte.comPharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $0 | $1.38M ▲ | $-8.42M ▼ | 0% | $-1.24 ▼ | $-1.38M ▲ |
| Q1-2026 | $0 | $848.3K ▼ | $-8.36M ▼ | 0% | $-1.23 ▼ | $-8.36M ▼ |
| Q4-2025 | $0 | $1.04M ▲ | $11.75M ▲ | 0% | $1.6 ▲ | $-1.04M ▼ |
| Q3-2025 | $0 | $960.25K ▼ | $-3.04M ▼ | 0% | $-0.44 ▼ | $-960K ▲ |
| Q2-2025 | $0 | $1.11M | $-1.47M | 0% | $-0.39 | $-1.11M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $15.61M ▲ | $55.98M ▲ | $19.42M ▲ | $1.32M ▼ |
| Q1-2026 | $13.44M ▼ | $45.11M ▼ | $1.52M ▼ | $43.59M ▼ |
| Q4-2025 | $15.54M ▼ | $55.17M ▲ | $3.28M ▼ | $51.89M ▲ |
| Q3-2025 | $16.76M ▼ | $43.83M ▼ | $3.58M ▼ | $40.25M ▼ |
| Q2-2025 | $20.84M | $55.1M | $11.65M | $43.45M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $-7.42M ▲ | $-979.52K ▲ | $-3M ▼ | $6.21M ▲ | $2.23M ▲ | $-979.52K ▲ |
| Q1-2026 | $-8.36M ▼ | $-1.99M ▼ | $0 | $0 ▲ | $-1.99M ▼ | $-1.99M ▼ |
| Q4-2025 | $11.75M ▲ | $-1.04M ▼ | $0 | $-171.54K ▲ | $-1.21M ▲ | $-1.04M ▼ |
| Q3-2025 | $-3.05M ▼ | $-509.89K ▲ | $0 ▼ | $-3.95M ▲ | $-4.46M ▲ | $-509.89K ▲ |
| Q2-2025 | $-1.47M | $-1.05M | $7M | $-10.74M | $-11.8M | $-1.05M |
CEO
Joshua N. Silverman
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2021-07-12 | Reverse | 1:1550 |
| 2003-12-08 | Forward | 3:1 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
GEODE CAPITAL MANAGEMENT, LLC
Shares:126.6K
Value:$115.84K
AYRTON CAPITAL LLC
Shares:92.09K
Value:$84.26K
EQUITEC PROPRIETARY MARKETS, LLC
Shares:82.73K
Value:$75.7K
Summary
Showing Top 3 of 28